文摘
这项研究是为了确定长期吸入激素治疗是否能诱发儿童哮喘缓解期,并决定什么时候稳定气道反应发生。因此,延长后续几个月的两组孩子参加了一个长期的干预研究。这前的研究表明,长期(平均随访22个月)与吸入激素治疗+β2受体激动剂可以改善症状、呼吸道口径和气道反应在儿童哮喘,独自与β2受体激动剂。吸入激素治疗+β2受体激动剂,呼吸道口径没有进一步改善后4个月,而挑衅的组胺导致一秒钟用力呼气量下降20% (PD20)组胺显示逐步改善没有达到明显的高原。缓解被定义为任何8月期间症状免费。58岁的孩子最初随机接收0.2毫克舒喘灵,+ 0.2毫克布地奈德,t.i.d。,five children withdrew: three due to lack of motivation, one for psychological reasons, and one due to a deterioration of asthma. One patient was hospitalized because of an asthma exacerbation. Airway calibre showed no improvement after 4 months up to 36 months. Mean PD20 histamine stabilized after 20 months at 2.1 doubling doses above baseline, but at a subnormal level of 80 micrograms. Symptoms improved during the first 18 months, and may have been improving further, but slowly, during the period between 18 and 36 months.(ABSTRACT TRUNCATED AT 250 WORDS)